Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ocrevus
Pharma
Roche touts near-complete MS suppression for injectable Ocrevus
Roche's subcutaneous Ocrevus helped 97% of multiple sclerosis patients achieve no relapse up to 48 weeks of treatment.
Angus Liu
Apr 17, 2024 11:00am
Roche's subcutaneous Ocrevus stacks up to original IV version
Oct 11, 2023 7:22am
As Roche rival draws near, TG crashes on subpar MS drug sales
Aug 2, 2023 11:00am
Roche scores with subcutaneous version of MS drug Ocrevus
Jul 13, 2023 10:18am
Intra-Cellular winner of the Fierce Madness Drug Ad Tournament
Mar 22, 2023 8:30am
Genentech increases visibility of Black women with MS
Feb 1, 2023 7:05am